Intratympanic steroids for Ménière's disease or syndrome

Extended phenotype and clinical subgroups in unilateral Meniere disease: A cross‐sectional study with cluster analysis

“…were not able to demonstrate any effects of diuretics, 27 betahistine or steroids; 28 these results could be explained by a biased selection of patients with different aetiologies. Further phenotyping of these clinical variants is needed for a better understanding of the clinical heterogeneity observed in MD.…”

Intratympanic therapy in Meniere's syndrome or disease: up to date evidence for clinical practice

“…Interest in the role of steroids for the treatment of inner ear diseases originates from the work of McCabe in 1979, 16 although the first published report of intratympanic steroid injection was described by Sakata et al in 1987. 17 It is postulated that the injection or instillation of steroids through the tympanic membrane into the middle ear allows absorption into the inner perilymph primarily via the round window membrane (other possible routes include via oval window annular ligament, otic capsule microfractures and the small lacunar mesh in the bony wall surrounding the inner ear 18 ).…”

“…tinnitus and imbalance); 4 Preventing progression of the disease, in particular the loss of hearing and balance function which characterises the disorder. 18 The two commonest steroid preparations used are dexamethasone and (methyl) prednisolone. Although animal studies 19 favoured methyl prednisolone relative to dexamethasone because it yielded 'higher concentrations' in the endolymph after intratympanic injections, re-interpretation of the results shows that dexamethasone is more efficacious.…”

Intratympanic Therapies for Menière’s Disease

“…Similarly, a Cochrane review in 2011 only identified a single randomized control trial, with a low risk of bias, that demonstrated a benefit for use of ITS in treating Menière’s disease. (18) Due to the heterogeneous nature of studies, additional research into the effectiveness of ITS is necessary.…”